Another major benefit is its effect on digestionOzempic slows gastric emptying, which helps keep you satisfied for longer periods after meals
The FDA-approved indications are: Semaglutide (Ozempic): Type 2 diabetes, cardiovascular risk reduction in type 2 diabetes patients Semaglutide (Wegovy): Chronic weight management in adults with BMI 30 or BMI 27 with weight-related comorbidity Tirzepatide (Mounjaro): Type 2 diabetes Tirzepatide (Zepbound): Chronic weight management in adults with BMI 30 or BMI 27 with weight-related comorbidity Liraglutide (Victoza): Type 2 diabetes, cardiovascular risk reduction Liraglutide (Saxenda): Chronic weight management Insurance companies write their formulary policies around FDA-approved indications
How to transition to weight maintenance after GLP-1 treatment depends on your medication response, appetite changes, labs, nutrition habits, movement routine, and whether continued treatment is medically appropriate
Insights Imaging 8 (6), 537548
Ro began by providing compounded versions of GLP-1 drugs, then struck deals with Lilly and Novo Nordisk to secure access to Ozempic, Wegovy and Zepbound